Glanbia (GLAPF) Q2 2026 Earnings Report

The call presents a strongly positive operational and financial picture: significant top-line growth, a 30% increase in adjusted EPS, upgraded guidance, strong cash conversion, and clear progress on transformation and digital initiatives. However, material near-term headwinds remain — notably record whey protein costs, some early price elasticity, supply-chain related raw material inflation (H&N) and one-off transformation charges — which management is actively addressing through pricing, procurement and efficiency measures. On balance, the positive performance, upgraded guidance and effective capital returns outweigh the challenges, but monitoring of input cost dynamics and consumer elasticity remains key.

Glanbia upgraded full‑year guidance, raising adjusted EPS growth to 17–20% in constant currency and guiding Performance Nutrition like‑for‑like revenue to 12–14% (H1 PN LFL +16.9%: volume +9.3%, price +7.6%; H1 PN EBITDA margin 12.6%), Health & Nutrition LFL revenue to 8–10% (H1 H&N LFL +12%; H1 H&N EBITDA $67.9m, margin 18.4%), and Dairy Nutrition EBITDA to $170–180m (H1 DN EBITDA $92.3m, +28.2%); group targets operating cash conversion above its 85% goal and expects year‑end net debt/adjusted EBITDA of ~1.0x (H1 net debt ~$731m; H1 net debt/EBITDA 1.4x), with FY capital expenditure $100–110m (H1 capex $50m, strategic $32m). Management increased transformation savings to $70m p.a. by 2027 (≈40% to be delivered by year‑end; total program charges ~$110m, $85m incurred), reaffirmed JV profit after tax guidance of ~ $20m, completed a EUR100m share buyback (~4.9m shares at EUR20.49) and raised the interim dividend 10% to EUR0.1892.